GlassScriptPhysician profile
Jill A Rys
NPI 1922080944
$5,143.09
in general payments reported to CMS, 2019-2025
26 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,402 · 2022: $1,414 · 2023: $1,376 · 2024: $655 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,326.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,803.24 | 2021-2025 | |
| Janssen Biotech, INC. | $571.35 | 2021-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $508.17 | 2021-2024 | Xifaxan, Plenvu, Uceris |
| Gilead Sciences, INC. | $349.58 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $258.91 | 2021-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $249.98 | 2021 | |
| Ardelyx, INC. | $207.20 | 2022-2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $156.89 | 2021-2024 | Entyvio, Gattex |
| Celgene Corporation | $146.84 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $129.04 | 2021-2022 | |
| Braintree Laboratories, INC. | $120.30 | 2021-2023 | Sutab, Suflave |
| Nestle Healthcare Nutrition INC. | $108.89 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $108.66 | 2021-2023 | Rebyota |
| Qol Medical, LLC | $96.35 | 2021-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $61.36 | 2021-2024 | Ocaliva |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $48.62 | 2021 | |
| Aimmune Therapeutics, INC. | $34.54 | 2024 | |
| Fresenius Kabi USA, LLC | $34.42 | 2023 | Idacio |
| Regeneron Healthcare Solutions, INC. | $27.20 | 2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $24.74 | 2024 | Iqirvo |
| Janssen Scientific Affairs, LLC | $18.64 | 2022 | |
| Lilly USA, LLC | $18.63 | 2025 | Omvoh |
| Intra-Sana Laboratories | $16.17 | 2021 | |
| Genzyme Corporation | $15.11 | 2022 | |
| Medtronic, INC. | $14.24 | 2022 | |
| Evoke Pharma, INC. | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Rys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.